Browsing Tag
Novo Nordisk
103 posts
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
Can 7.2 mg Wegovy redefine the weight loss standard in obesity treatment?
Novo Nordisk files for FDA approval of 7.2 mg Wegovy with fast-track priority review. See what this higher dose means for the future of obesity treatment.
Is Eli Lilly the NVIDIA of healthcare? How metabolic drugs became the new AI trade
Discover how Eli Lilly and Company crossed the $1 trillion valuation mark and why its metabolic-health franchise is now being valued like a high-growth tech platform—read more now.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!